Peter Zdziarski/LinkedIn
Feb 18, 2026, 15:24
Peter Zdziarski: How Glanzmann Thrombasthenia Suddenly Became ‘Mainstream’?
Peter Zdziarski, Vice President and Marketing Director at Glanzmann’s Research Foundation, shared a post on LinkedIn։
”Recently posted in the incredible Glanzmann Thrombasthenia Support Group (with almost 1 thousand patients, family members, and doctors!)
Just thinking out loud:
Has anyone else noticed how GT suddenly became ‘mainstream’?
And just as fast, a wave of unknown experts showed up out of nowhere?
I wish I knew why, but the point is this:
You are the expert in your GT. Your lived experience matters more than any trending take.
I know our community has been cautious about attention in the past. But let’s take advantage of the spotlight and turn it into new treatments and possibly even gene therapy!”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments